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Abstract
Background: We conducted a case-control study in the greater Toronto area to evaluate potential lung cancer risk 
factors including environmental tobacco smoke (ETS) exposure, family history of cancer, indoor air pollution, workplace 
exposures and history of previous respiratory diseases with special consideration given to never smokers.
Methods: 445 cases (35% of which were never smokers oversampled by design) between the ages of 20-84 were 
identified through four major tertiary care hospitals in metropolitan Toronto between 1997 and 2002 and were 
frequency matched on sex and  ethnicity with 425 population controls and 523 hospital controls. Unconditional 
logistic regression models were used to estimate adjusted odds ratios (OR) and 95% confidence intervals (CI) for the 
associations between exposures and lung cancer risk.
Results: Any previous exposure to occupational exposures (OR total population 1.6, 95% CI 1.4-2.1, OR never smokers 
2.1, 95% CI 1.3-3.3), a previous diagnosis of emphysema in the total population (OR 4.8, 95% CI 2.0-11.1) or a first degree 
family member with a previous cancer diagnosis before age 50 among never smokers (OR 1.8, 95% CI 1.0-3.2) were 
associated with increased lung cancer risk.
Conclusions: Occupational exposures and family history of cancer with young onset were important risk factors 
among never smokers.
Background
Lung cancer is the most common type of cancer and the
leading cause of cancer death in Canada with approxi-
mately 23,400 new cases (14.3 percent of all new cancers
among males, 13.1 percent among females) and 20,500
deaths annually [1]. Although active tobacco smoking has
been well established as the major cause of lung cancer
[2-5], the etiology among never smokers beyond ETS
exposure [6] remains to be elucidated and is of great pub-
lic health importance [7,8]. The influences of indoor air
pollution, workplace exposures and previous history of
respiratory disease on lung cancer development among
never smokers require additional investigation.
To further understand the etiology of lung cancer, with
special consideration given to never smokers, we con-
ducted a case-control study in the greater Toronto area
with oversampling among never smokers. The objective
of this study was to evaluate potential lung cancer risk
factors including ETS exposure, family history of cancer,
indoor air pollution, workplace exposures and history of
previous respiratory diseases.
Methods
Study population and data collection
The case series consisted of incident cases of cancer of
the trachea, bronchus or lung diagnosed among men and
women between the ages of 20 and 84. Cases were identi-
fied between 1997 and 2002 through four major tertiary
care hospitals in metropolitan Toronto that have the larg-
est lung cancer services for surgical and medical oncol-
ogy, including the two centres that see all patients who
* Correspondence: John.McLaughlin@cancercare.on.ca
1 Prosserman Centre for Health Research, Samuel Lunenfeld Research Institute, 
60 Murray St., Toronto, M5T 3L9, Canada
Full list of author information is available at the end of the articleBrenner et al. BMC Cancer 2010, 10:285
http://www.biomedcentral.com/1471-2407/10/285
Page 2 of 9
Table 1: Demographic characteristics of lung cancer patients and controls in a population based case-control study, 
Greater Toronto Area, Ontario, 1997- 2002
Case, n(%) Control, n(%)
Smokers Never smokers Total Smokers Never smokers Total p valuea
Total 289 156 445 482 466 948
Gender
Male 163 (56) 46 (30) 209 (47) 241 (50) 145 (31) 386 (41) p = 0.03
Female 126 (44) 110 (70) 236 (53) 241 (50) 321 (69) 562 (59)
Age
< 35 1 (< 1) 10 (6) 11 (3) 58 (12) 86 (18) 144 (15)
35-45 9 (3) 21 (13) 30 (7) 77 (16) 89 (19) 166 (180
45-55 34 (12) 27 (17) 61 (14) 88 (18) 85 (18) 173 (18)
55-65 63 (22) 28 (18) 91 (20) 101 (21) 88 (19) 189 (20)
65-75 131 (45) 57 (37) 188 (42) 100 (21) 71 (15) 170 (18)
> 75 51 (18) 13 (8) 64 (14) 58 (12) 48 (10) 106 (11)
Age, Mean ± SD 66 ± 10 59 ± 13 64 ± 12 56 ± 16 53 ± 17 54 ± 16 < .0001
Ethnicity
White 255 (88) 97 (62) 352 (79) 429 (89) 346 (74) 775 (82) p = 0.07
Asian 21 (7) 48 (31) 69 (16) 27 (6) 78 (17) 105 (11)
Other 13 (5) 11 (7) 24 (5) 26 (5) 42 (9) 68 (7)
Education
< 8 years 97 (34) 36 (23) 137 (31) 55 (11) 68 (15) 140 (15) < .0001
8-11 years 137 (47) 52 (33) 189 (42) 212 (44) 187 (40) 399 (42)
≥12 years 55 (19) 64 (41) 119 (27) 205 (43) 204 (44) 409 (43)
All types of smoking combined
Never 156 156 (35) 466 466 (49) < .0001
Former (> 2 yrs. Since quitting) 159 (55) 159 (36) 319 (66) 319 (34)
Current 130 (45) 130 (29) 163 (34) 163 (17)
Pack-yearsb, Mean ± SD 45 ± 35 25 ± 27 < .0001
Histology
Adenocarcinoma 80 (28) 76 (49) 156 (35)
Squamous cell carcinoma 68 (24) 9 (6) 77 (17)
Small-cell carcinoma 28 (10) 4 (3) 32 (7)
Large cell carcinoma 21 (7) 6 (4) 27 (6)
Others/Mixed 46 (16) 26 (17) 72 (16)
Not classified/clinical
diagnosis
46 (16) 35 (22) 81 (18)
a p-values from χ2 test or t-test across cases and controls
b Pack-years among ever and current smokersBrenner et al. BMC Cancer 2010, 10:285
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require radiotherapy. Diagnoses were histologically con-
firmed by a pulmonary pathologist following classifica-
tion according to the ICD for oncology-3 [9]. As one of
the main objectives of the study was to study lung cancer
etiology other than from tobacco exposure, among never
smokers, we therefore over sampled never smoking lung
cancer patients, leading to 35% of the total cases being
never smokers. A total of 445 eligible cases and 948 con-
trols were recruited into the study for whom consent was
obtained. Controls were residents of metropolitan
Toronto who did not have cancer at the time of recruit-
ment. Population-based controls were randomly sampled
from property tax assessment files (n = 425). Hospital-
based controls were sampled from patients seen in the
Mount Sinai Hospital Family Medicine Clinic (n = 523),
which is a non-specialty, family medicine practice situ-
ated within the hospital where recruitment into the study
was conducted independent of reason for visit to the
clinic. Controls were frequency matched with cases on
sex and ethnicity. Participation rates were similar
between cases (62%, 445 of 716 total eligible, 116 refused
participation, whereas the remaining patients died before
study entry and/or complete data collection was possible)
and population controls, (60%, 425 of total 718 eligible)
and slightly higher among hospital controls (84%, 523 of
621 total eligible). Informed consent was obtained from
all participants and approvals were obtained from the
Research Ethics Board.
Exposure Information
Participants' lifetime information concerning tobacco
consumption, exposure to ETS exposure, air pollution
from heating, workplace exposures to potential lung car-
cinogens, family history of cancer and health history were
collected through a detailed questionnaire administered
via interview either in person or over the telephone.
'Never smokers' were defined as those who had not
smoked more than 100 cigarettes in their lifetime. 'For-
mer smokers' were smokers who had stopped smoking
for at least two years at the date of the interview. Cumula-
tive tobacco exposure was estimated in pack-years, where
a pack is 20 cigarette equivalents.
Environmental tobacco smoke (ETS) exposure was cat-
egorized as having been exposed to second hand smoke
either during childhood, as an adult or at work, with
duration in years categorized to examine dose-response
relationships. Indoor air pollution from heating was col-
lected for oil, gas, coal & wood sources, with the duration
of each exposure recorded. A measure of solid fuels for
heating (coal and wood) was also created to examine the
potential for differential effects of heating sources with
particulate matter emission. Workplace exposures to
potential lung carcinogens including asbestos, paints
and/or solvents, welding equipment, pesticides, grain ele-
vator dust, wood dust and smoke, soot or exhaust (not
from tobacco) were dichotomized as exposed or unex-
posed. Family history was classified as the number of first
Table 2: The association between ETS and risk of lung cancer among never smokers in a population based case-control 
study, Greater Toronto Area, Ontario, 1997-2002
Total Population n = 1393 Never smokers n = 622
Case, n Control, n ORa 95%CI Case, n Control, n ORb 95%CI
445 948 156 466
ETS Exposure
None 29 88 Refc 23 68 Refd
At home Adult and/or Child 375 772 1.2 0.7-1.9 109 341 1.1 0.6-1.9
Childhood 333 672 1.1 0.7-1.9 93 298 1.0 0.6-1.8
Adulthood 226 439 1.0 0.6-1.7 50 247 1.0 0.5-2.0
At work 259 463 1.3 0.9-1.9 69 179 1.2 0.7-2.1
< 10 years 73 194 1.1 0.8-1.6 32 90 1.3 0.8-2.2
> 10 years 176 261 1.2 0.9-1.6 37 86 1.2 0.7-2.0
At both home and work 226 405 1.4 0.9-2.2 50 142 1.2 0.7-2.1
aOR is adjusted for pack-years of smoking, age, sex, education and ethnicity
bOR is adjusted for age, sex, education and ethnicity
cReference group consists of all participants with no ETS exposure
dReference group consists of never-smokers with no ETS exposureBrenner et al. BMC Cancer 2010, 10:285
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degree relatives with any cancer, lung cancer, or aerodi-
gestive tract cancers with distinction by relative types.
Statistical Analysis
Differences in demographics between cases and controls
as well as between control types were evaluated using χ2
tests and t-tests. Multivariate unconditional logistic
regression models were used to obtain odds ratio (OR)
estimates and 95% confidence intervals (CI) for the asso-
ciations between exposures and lung cancer risk,
adjusted for cumulative tobacco exposures (pack-years),
age (years), gender, education and ethnicity. Given that
cases were sampled based on smoking status, all analyses
were adjusted for smoking and the focus of this investiga-
tion is on factors other than tobacco. Indicator variables
were created for all categorical variables in analyses. We
stratified analyses by years of exposure and age of onset
when applicable in an attempt to determine the tempo-
rality of potential exposure-disease associations. Analyses
were conducted using SAS Version 9.1 (SAS V9.1; SAS
Institute Inc, Cary NC, USA).
We also applied the Spitz (2007) [10] and Liverpool
Lung Project (2008) [11] lung cancer risk models to eval-
uate the predictive ability of their models within our pop-
ulation. We stratified our population by smoking status to
examine the area under the curve and Hosmer Lemeshow
goodness-of-fit statistics [12] within the subgroups. Pre-
vious history of hay fever and dust exposure were not
available in our study and were thus not included as part
of the Spitz model.
Results
Table 1 shows the frequency distribution of demographic
variables and smoking for cases and controls. Controls
were younger and more educated. There was a higher
percentage of never smokers among controls than cases.
Table 3: The association between workplace exposures and risk of lung cancer in a population based case-control study, 
Greater Toronto Area, Ontario, 1997-2002
Total Population n = 1393 Never smokers n = 622
Case, n Control, n ORa 95%CI Case, n Control, n ORb 95%CI
445 948 156 466
No previous exposures 261 691 Refc 104 371 Refd
Any occupational exposure 191 275 1.6 1.4-2.1 52 95 2.1 1.3-3.3
Ever worked with/been exposed to:
Asbestos 31 51 1.1 0.6-2.0 5 16 1.0 0.3-3.0
Solvents, paints or thinners 107 152 1.6 1.2-2.3 33 54 2.8 1.6-5.0
Welding equipment 33 43 1.7 1.0-3.0 7 11 3.4 1.1-10.4
Pesticides 21 24 1.6 0.8-3.1 3 6 1.1 0.2-5.3
Grain elevator dust 12 19 1.1 0.5-2.4 3 7 1.1 0.3-4.6
Wood dust 47 80 1.5 1.0-2.4 11 26 1.8 0.8-4.2
smoke-soot or exhaust 75 99 1.7 1.2-2.5 21 33 2.8 1.4-5.3
other than tobacco
aOR is adjusted for pack-years of smoking, age, sex, education and ethnicity
bOR is adjusted for age, sex, education and ethnicity
cReference group consists of all participants with no previous workplace exposures
dReference group consists of never smokers with no previous workplace exposuresBrenner et al. BMC Cancer 2010, 10:285
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Among cases, adenocarcinoma was the most common
histological subtype with a higher proportion of adeno-
carcinomas among never smoking cases. Never smoking
cases also consisted of a higher proportion of females and
Asians and were on average younger at diagnosis (p <
.0001). When examining demographic differences
between population and hospital based controls, controls
varied across gender, education, age groups and smoking
groups. However, when examining age and pack-years
smoking as included in regression models, we observed
no significant differences across control types.
Cases and controls did not vary significantly in the total
hours exposed to ETS during childhood or adulthood at
home (data not shown). Among never smokers in our
population, we observed no association between either
exposure to ETS at home or at the workplace and lung
cancer risk (Table 2). In general, the effect estimates for
ETS exposure were similar between the total population
and only among never smokers. In terms of indoor air
pollution, we did not observe a significant association
between heating source (coal and/or wood) and lung can-
cer risk among never smokers (OR 1.5, 95% CI 0.1-2.8).
The association between occupational exposures to
asbestos, solvents, paints or thinners, welding equipment,
pesticides, grain elevator dust, wood dust and smoke,
soot or exhaust (from sources other than tobacco) and
lung cancer risk is shown in Table 3. Occupational expo-
sure to any of the putative lung carcinogens was associ-
ated with lung cancer risk in the total population (OR 1.6,
95% CI 1.4-2.1). Among never smokers, the odds ratio for
Table 4: The association between previous medical history and risk of lung cancer in a population based case-control 
study, Greater Toronto Area, Ontario, 1997-2002
Total Population n = 1393 Never smokers n = 622
Case, n Control, n ORa 95%CI Case, n Control, n ORb 95%CI
445 948 156 466
Emphysema
Never 414 940 1.0 Ref 154 465 1.0 Ref
Ever 31 8 4.8 2.0-11.1 2 1 3.1 0.3-35.9
Chronic Bronchitis
Never 424 899 1.0 Ref 153 440 1.0 Ref
Ever 21 49 0.9 0.5-1.7 3 26 0.4 0.1-1.5
Asthma
Never 388 835 1.0 Ref 140 408 1.0 Ref
Ever 57 113 1.2 0.8-1.8 16 58 1.0 0.5-1.9
Pneumonia
Never 434 913 1.0 Ref 151 456 1.0 Ref
Ever 11 35 0.6 0.3-1.2 5 10 1.9 0.6-6.2
Tuberculosis
Never 439 943 1.0 Ref 153 463 1.0 Ref
Ever 6 5 2.6 0.7-9.2 3 3 2.2 0.4-12.5
Other respiratory illness
Never 385 823 1.0 Ref 139 403 1.0 Ref
Ever 60 125 1.1 0.8-1.6 17 63 0.9 0.5-1.7
aOR is adjusted for pack-years of smoking, age, sex, education and ethnicity
bOR is adjusted for age, sex, education and ethnicityBrenner et al. BMC Cancer 2010, 10:285
http://www.biomedcentral.com/1471-2407/10/285
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exposure to any of the putative carcinogens was 2.1 (95%
CI 1.3- 3.3). Specifically among never smokers, exposure
to solvents, paints or thinners conferred an OR of 2.8
(95% CI 1.6-5.0), while exposure to welding equipment
conferred an OR of 3.4 (95% CI 1.1-10.4) and exposure to
smoke, soot or exhaust (other than tobacco) conferred an
OR of 2.8 (95% CI 1.4-5.3). We did not observe significant
associations for exposures to asbestos, pesticides, grain
elevator dust, and wood dust among never smokers in
our study.
With regard to previous medical history of respiratory
conditions, we observed a significant increase in lung
cancer risk associated with a previous diagnosis of
emphysema among the total population (OR 4.8, 95 % CI
2.0-11.1) (Table 4). When stratified by age at onset, those
with age of onset of emphysema greater than 50 years old
had a significant increase in lung cancer risk (OR 4.2, 95%
CI 1.0-10.9), whereas among those less than 50 years of
age, the risk was not significant (OR 4.0, 95% CI 0.6-27.5)
(Data not shown). None of the other previous conditions
we investigated (asthma, chronic bronchitis, pneumonia
or tuberculosis) were associated with increased risk. In a
model including all previous lung disease, the effects of
emphysema maintained significance.
We did not observe a significant association between
family history of cancer and lung cancer risk, except
among those with affected relatives with young onset (<
50 years of age) cases (Table 5). Among never smokers
having a relative with young onset cancer was associated
with a significant increase in risk (OR 1.8, 95% CI 1.0-3.2,
(p = 0.04)). An increasing number of first degree relatives
with a previous history of any cancer suggested an
increase in risk for having 2 or more family members.
Trend statistics for increasing number of first degree rela-
tives with cancer were, however, not significant (p-trend
= 0.2). No association was detected when data were ana-
lyzed by the type of affected relatives (data not shown).
Applying the Spitz risk model indicated that there was
only modest predictive ability among never smokers in
our population (Area under the Curve (AUC) 0.525).
Among smokers (current and former), however, the Spitz
model was shown to have better predictive power, (AUC
former smokers = 0.716, current smokers = 0.780),
despite our study not possessing data for hay fever or dust
exposure. The Liverpool Lung Project risk model pro-
vided similar outcomes in prediction, identifying cases in
the total population well (AUC 0.788) with lower statis-
tics when applied to only never smokers in the population
(AUC 0.721).
Discussion
In this study we investigated the impact of several factors
on lung cancer risk overall as well as specifically among
never smokers. The most important risk factors we
observed among never smokers were exposure to poten-
tial occupational carcinogens, family history of cancer
with young onset and previous history of respiratory dis-
eases among the total population.
Table 5: The association between family history of previous cancer and risk of lung cancer in a population based case-
control study, Greater Toronto Area, Ontario, 1997-2002
Total Population n = 1393 Never smokers n = 622
Case, n Control, n ORa 95%CI Case, n Control, n ORb 95%CI
445 948 156 466
No family history of any cancer 246 563 1.0 Refc 95 293 1.0 Refd
Positive family history of any cancer
1 141 292 1.1 0.8-1.4 42 134 0.9 0.6-1.4
2 or more 58 93 1.3 0.9-1.9 19 39 1.4 0.8-2.8
Affected relatives age at onset < 50 82 126 1.3 0.9-1.9 28 48 1.8 1.0-3.2
Positive family history of aero-digestive cancer 45 78 1.2 0.8-1.8 11 34 0.9 0.4-1.9
Positive family history of lung cancer 30 63 1.0 0.6-1.7 8 26 0.9 0.4-2.1
aAdjusted for pack-years smoking, age, sex, education and ethnicity
bAdjusted for age, sex, education and ethnicity
cReference group consists of all participants with no family history of cancer
dReference group consists of never smokers with no family history of cancerBrenner et al. BMC Cancer 2010, 10:285
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In our examination of the effects of several occupa-
tional exposures among never smokers in the greater
Toronto area we found several significant potential
sources of increased risk including exposure to solvents,
paints or thinners, welding equipment and smoke, soot or
exhaust (from sources other than tobacco). This informa-
tion is important as data concerning occupational expo-
sures and lung cancer among never smokers are still
lacking in the literature [13].
Our results support the concept that exposure to
exhaust fumes and or soot/smoke (from non-tobacco
sources) is a source of carcinogenic exposure. A previous
meta-analysis suggested that when adjusted for smoking,
heavy diesel exhaust exposure was associated with an
increased risk (OR 1.4, 95% CI 1.3-1.6) [14], and a recent
study examining the effects in a similar Canadian popula-
tion, was also suggestive of increased risk (OR 1.6, 95% CI
0.9-2.8) [15]. With regards to soot and exhaust exposure,
these substances contain benzo[a]pyrene, a known car-
cinogen, and has been consistently shown to increase risk
[16,17]. We observed an increased risk associated with
exposure to paints, thinners and solvents, which was in
agreement with previous studies [18-22]. When ingested,
these substances can affect the pleural membranes, caus-
ing scarring and or mutations, thus increasing the poten-
tial for carcinogenesis [23]. Similarly, exposure to welding
equipment was associated with increased risk as
observed in a meta-analysis of welding and lung cancer
[24]. Wood dust is a known carcinogen associated with
the development of cancers of the respiratory tract [25-
27]. In this study the estimate for wood dust exposure
was suggestive of increased risk among never smokers.
While these observations require replication, they are
consistent with the overall patterns seen for wood dust,
with the potential implication that workplace exposures
should be controlled and monitored. Asbestos exposure
has been previously shown to have an effect on lung can-
cer risk [28,29]; however, no association between lung
cancer and asbestos was seen here among never smokers,
contrary to previously published results [30]. The dis-
crepancies with the previous studies may be due to an
attenuation of the risk estimate as a result of the simple
dichotomy used to indicate asbestos exposure which may
not distinguish between actual or potential exposure
among the small number of individuals reporting expo-
sure in this non-occupational cohort. Overall, these
observations provide support for efforts to control, moni-
tor and reduce exposures to potentially hazardous work-
place exposures, which in this study are shown to be
associated with lung cancer, even among never smokers.
Our findings are consistent with the evidence suggest-
ing that a previous history of acquired respiratory condi-
tions is a risk factor for lung cancer [31-41]. Chronic
inflammation and airway obstruction may predispose
individuals to various types of cancer as the damage cre-
ated by acquired pulmonary diseases such as chronic
obstructive pulmonary disease (COPD) may be involved
in cancer development [42-47]. Proposed biological
mechanisms include enhanced effects of carcinogenic
exposures in the presence of chronic inflammation or a
compromised immune response [48,49], as well as the
possibility of lung cancer evolving directly from the scar
lesions created by non-malignant conditions [50,51].
Although the analyses performed here accounted for
active smoking, it is still possible that the relationship
between acquired respiratory disease and lung cancer is
partially explained by residual confounding from tobacco
[52]. In addition, due to the relatively small numbers fur-
ther investigations among never smokers is still war-
ranted. Further elucidation and characterization of the
genetic variants associated with inflammation of the
lungs may also help to clarify the role of acquired respira-
tory conditions in the etiology of lung cancer.
ETS exposure was not found to significantly increase
risk among never smokers in this study, however, several
potential explanations are possible. ETS exposure either
as a child or an adult in the home or the workplace has
been evaluated in numerous studies [53]. The results,
however, have been inconsistent as to the significance
and magnitude of the effects among never smokers.
When estimates were pooled in a meta-analysis of 34
case-control studies of non-smokers, a pooled relative
risk of 1.2 (95% CI 1.1-1.4) was observed, although only
seven out of 34 studies reporting significantly elevated
risk [6]. It was suggested that the inconsistency in the sig-
nificance of findings across studies could be due to issues
of sample size, measurement error, recall bias and con-
founding [54]. Despite our efforts to minimize misclassi-
fication bias by collecting data on involuntary tobacco
smoke exposure data for home, work and other exposure
locations during both childhood and adulthood, the pos-
sibility of these issues cannot be excluded. The main limi-
tation in our study is the lack of power to detect a modest
effect. Non-differential misclassification of the dichoto-
mous exposures may also lead to a bias toward to null.
We combined hospital and population based controls in
an attempt to increase our sample size and in turn the
ability to detect significant associations. In order to
address any issues created by this pooling we investigated
effect estimates among only population based controls.
Effect estimates were of a similar magnitude and no sig-
nificant associations were observed among population
based controls that were not observed among the total
population.
Another limitation of this study is its dependence on
self-reported exposures. Previous history of respiratory
disease was self-reported as access to patient medical
records was not available for validation, and similarly, val-Brenner et al. BMC Cancer 2010, 10:285
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idation of occupation was not possible due to a lack of
occupational records. Even so, this study provides risk
estimates for a relatively large group of never smoking
lung cancer cases in a population-based study, and thus
yields findings that are of increasing relevance given
recent changes in tobacco use in the population. The
detailed risk factor information concerning indoor air
pollution and family history collected from patients fol-
lowing diagnosis, as well as similar participation rates
among cases and controls are additional strengths of the
study.
When applying previously specified risk prediction
models to our population, both models were able to ade-
quately predict outcomes among smokers, however, both
models had substantially less predictive ability among
never smokers. This indicates that previously identified
risk prediction models have little utility among never
smokers and that additional determinants of increased
risk or susceptibility must still be identified among this
group. Identification of these new factors among never
smokers has been difficult due to the small numbers of
never smoking cases in studies to date. With the develop-
ment of large-scale collaborations and consortia [55], it
will become possible for much more detailed risk models
to be evaluated among larger populations of never smok-
ers, leading ultimately to improved risk prediction and
understanding of lung cancer etiology among never
smokers.
This study mainly assessed environmental risk factors
for the development of lung cancer in never smokers. It is
now clear that the molecular pathogenesis of lung cancer
in smokers and non-smokers is different, with a higher
proportion of adenocarincoma observed among never
smoking cases. Recent studies have demonstrated that
activating mutations in the EGFR tyrosine kinase domain
occur much more frequently in lung cancers in non and
never smoking patients. Furthermore, these mutations
are found significantly more often in adenocarcinomas,
women, and individuals of Asian origin where the muta-
tion rate can reach 60% in patients with these characteris-
tics [56]. These characteristics were all significantly
higher in our never smoking subset. Unfortunately, we do
not have adequate tissue samples to assess mutation sta-
tus in our cases, but studies of the interaction between
EGFR mutations and environmental factors deserve fur-
ther investigation.
Conclusion
In conclusion, occupational exposures displayed the
strongest associations with increased lung cancer risk
among never smokers in this study. Further understand-
ing of the role of these factors in lung cancer etiology may
ultimately lead to improved lung cancer prevention strat-
egies for the whole population.
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